Telomir publishes peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC and prostate models

Telomir Pharmaceuticals, Inc.

Telomir-Zn inhibits KDM histone demethylases by depleting intracellular iron; iron-rescue experiments confirmed mechanism specificity in TNBC cells.
In HCC1806 TNBC xenografts, Telomir-Zn significantly reduced metastatic dissemination; combined with paclitaxel in BT-549 models showed synergistic tumor reduction.
In prostate cancer model, oral Telomir-Zn reactivated silenced tumor-suppressor genes STAT1, GSTP1, RASSF1A, CDKN2A, and MASPIN.
Selective killing: TNBC cancer cells killed at low concentrations while normal cells unharmed at >50-fold higher concentrations; MDA-MB-231 xenografts did not respond.
Data supports planned Phase 1/2 TNBC trial under active FDA IND; CEO Erez Aminov cites limited options for advanced TNBC patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.